Investors of Regeneron Pharmaceuticals Encouraged to Join Class Action Lawsuit

Opportunity for Investors in Regeneron Pharmaceuticals

The Schall Law Firm, a prominent national litigation firm specializing in shareholder rights, is calling upon investors of Regeneron Pharmaceuticals, Inc. to review their involvement in a class action lawsuit. This legal action is centered around potential violations of securities laws, particularly under the Securities Exchange Act of 1934 and Rule 10b-5.

Background of the Case

The class action lawsuit pertains specifically to investors who acquired Regeneron securities between November 2, 2023, and October 30, 2024. Allegations have surfaced that during this timeframe, Regeneron made false or misleading statements that might have significantly affected the stock's value and led to investor losses. As part of the allegations, the complaint indicates that Regeneron engaged in practices that undermined the integrity of the stock market and deceived investors.

Key Allegations Against Regeneron

The crux of the accusations is that Regeneron improperly influenced the market perception of its flagship drug, Eylea. Reports suggest that the company subsidized credit card fees for distributors. These arrangements resulted in lowering the price of Eylea, which was intended to enhance sales figures misleadingly. The lawsuit claims these actions not only contravened regulatory standards but also inflated the average selling price (ASP) of Eylea, thereby violating the False Claims Act.

When the truth emerged regarding these practices, it is alleged that the value of Regeneron's stock suffered significantly, inflicting financial harm upon those who had invested during the stated class period.

Call to Action for Investors

Investors who feel they have been adversely affected are strongly encouraged to join the legal action. The Schall Law Firm is committed to representing the interests of shareholders and facilitating recovery for those who have sustained losses due to such unlawful practices. If you invested in Regeneron during the specified timeframe and wish to discuss your legal rights, you can reach out to the firm directly. Brian Schall is leading the efforts at the firm, which is located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. Contact can also be made through the firm's website, providing a gateway for concerned investors to seek advice at no upfront cost.

Important considerations

It’s crucial for potential class members to remember that the class has not been certified yet. Until such certification is in place, individuals are not officially represented by the legal team. Those who choose not to engage will remain as absent class members and may miss the opportunity for recovery.

In conclusion, the Schall Law Firm is reaching out to ensure that Regeneron investors have the opportunity to regain their losses through this class action lawsuit. Given the circumstances surrounding the allegations, action must be taken before March 10, 2025, to qualify for participation. The timeline is tight, and potential claimants are urged to assess their positions and act promptly.